tokens: As an oral , nontoxic compound with a mechanism of action distinct from that of ABL tyrosine kinase inhibition , FTI SCH66336 shows promise for the treatment of BCR / ABL induced leukemia .
folded_tokens: as a oral , nontoxic compound with a mechanism of action distinct from that of ABL tyrosine kinase inhibition , FTI sch66336 show promise for the treatment of bcr / abl induce leukemia .